hand foot and mouth disease
Conditions
Interventions
ultrasonic aerosol inhalation group:supportive and symptomatic treatment+ inhaled ultrasonically nebulized rHuIFN-alpha1b (20ug freeze-dried powder of rHuIFN-alpha1b dissolved in 4ml physiological sa
intramuscular injection group:supportive and symptomatic treatment +rHuIFN-alpha1b (20ug freeze-dried powder of rHuIFN-alpha1b dissolved in 1ml physiological saline) by intramuscular injection
control group:supportive and symptomatic treatment
Sponsors
The First Affiliated hospital of Zhengzhou University
Eligibility
Sex/Gender
All
Age
1 Years to 5 Years
Inclusion criteria
Inclusion criteria: Age from 0.5 to 5 years, according to the clinical diagnostice criteria fo HFMD, having one of followting clinical manifestations: 1. fever, axillary temperature higher than 38.5 degree; 2. neurological complications, including mental fatigue, irritability, headache, comiting, convalsions, limb weekness; 3. under rest state, respiratoty frequency(RF) more than 30, heart rate (HR)more than 140, and stool specimen was postive for EV71 by real-time RT-PCR.
Exclusion criteria
Exclusion criteria: 1. the critically HFMD patients,whose treatment was complicated by central respiratoy failure or who had brain-stem encephalitis, acute flaccid paralysis, neurogenic pulmonary edema, neurogenic shock or other severe symptoms and required endotracheal intubation and mechanical ventilation; 2. allergic constitution, especially allergic to multiple antibiotics or interferon products; 3. congenital heart diseas; 4. epilepsy and other central nervous system dysfuntion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the time of temperature normalization;the time of skim rash disapparement;Change of the EV71 burden before and after treatment;Rate of temperature normalization; | — |
Countries
China
Contacts
Public ContactSheng Guangyao
Outcome results
None listed